TU-2218 is under clinical development by TiumBio and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TU-2218’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NCE-401 (TU-2218, SKI-2218) is under development for the treatment of advanced solid tumors, cervical cancer, cholangiocarcinoma, colorectal cancer and idiopathic pulmonary fibrosis. The drug candidate is a new chemical entity. It acts by targeting TGF beta receptor type 1 (ALK5) and VEGFR2. It was under development for the treatment of renal fibrosis. It is administered through oral route.
TiumBio is a drug discovery company. The company’s pipeline products include chemical entity based drugs such as NCE401, NCE403, NCE406 and new biopharmaceuticals such as NBP604, NBP611 and NBP. It develops therapies for the treatment of idiopathic pulmonary fibrosis, endometriosis, uterine fibroids, prostate cancer, type 2 diabetes mellitus, hemophilia and rare diseases. TiumBio is headquartered in Seongnam-si, Gyeonggi-do, Korea
For a complete picture of TU-2218’s drug-specific PTSR and LoA scores, buy the report here.